Irreversible renal damage after transient renin-angiotensin system stimulation: involvement of an AT1-receptor mediated immune response

PLoS One. 2013;8(2):e57815. doi: 10.1371/journal.pone.0057815. Epub 2013 Feb 28.

Abstract

Transient activation of the renin-angiotensin system (RAS) induces irreversible renal damage causing sustained elevation in blood pressure (BP) in Cyp1a1-Ren2 transgenic rats. In our current study we hypothesized that activation of the AT1-receptor (AT1R) leads to a T-cell response causing irreversible impairment of renal function and hypertension. Cyp1a1-Ren2 rats harbor a construct for activation of the RAS by indole-3-carbinol (I3C). Rats were fed a I3C diet between 4-8 weeks of age to induce hypertension. Next, I3C was withdrawn and rats were followed-up for another 12 weeks. Additional groups received losartan (20 mg/kg/day) or hydralazine (100 mg/kg/day) treatment between 4-8 weeks. Rats were placed for 24h in metabolic cages before determining BP at week 8, 12 and 20. At these ages, subsets of animals were sacrificed and the presence of kidney T-cell subpopulations was investigated by immunohistochemistry and molecular marker analysis. The development of sustained hypertension was completely prevented by losartan, whereas hydralazine only caused a partial decrease in BP. Markers of renal damage: KIM-1 and osteopontin were highly expressed in urine and kidney samples of I3C-treated rats, even until 20 weeks of age. Additionally, renal expression of regulatory-T cells (Tregs) was highly increased in I3C-treated rats, whereas the expression of T-helper 1 (Th1) cells demonstrated a strong decrease. Losartan prevented these effects completely, whereas hydralazine was unable to affect these changes. In young Cyp1a1-Ren2 rats AT1R activation leads to induction of an immune response, causing a shift from Th1-cells to Tregs, contributing to the development of irreversible renal damage and hypertension.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biomarkers / metabolism
  • Hemodynamics / drug effects
  • Hydralazine / pharmacology
  • Hypertension / immunology
  • Hypertension / metabolism
  • Hypertension / pathology
  • Hypertension / physiopathology
  • Kidney / drug effects
  • Kidney / metabolism
  • Kidney / pathology*
  • Kidney / physiopathology*
  • Losartan / pharmacology
  • Rats
  • Rats, Transgenic
  • Receptor, Angiotensin, Type 1 / metabolism*
  • Renin-Angiotensin System / drug effects
  • Renin-Angiotensin System / immunology*
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology
  • Time Factors

Substances

  • Biomarkers
  • Receptor, Angiotensin, Type 1
  • Hydralazine
  • Losartan

Grants and funding

This work was performed within the framework of Dutch Top Institute Pharma, project “Renin-Angiotensin system blockade beyond Angiotensin II (T2-301)”. All the funding received for this study came from the Dutch Top Institute Pharma. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.